Around 47,700 men are diagnosed with prostate cancer in the UK each year, making it the most common cancer in men in the UK. It develops in the prostate, a walnut-sized gland found at the base of the bladder.
A hormone therapy has been rejected for some adults with newly-diagnosed, advanced prostate cancer.
A targeted cancer drug, already licensed for treating some breast and ovarian cancers, is found to be effective for some men with advanced prostate cancer.
A hormone therapy has been approved for NHS use in Scotland for some people with newly diagnosed, advanced prostate cancer for the first time.
A prostate cancer drug won’t be offered on the NHS any earlier in the treatment plans of patients living with the disease in England.
Our scientists have uncovered a new marker that’s found on treatment-resistant prostate cancer cells.
Researchers have launched a clinical trial to develop a breath test, analysing molecules that could indicate the presence of cancer at an early stage.
A type of specialist MRI scan has been recommended as one of the first tests for diagnosing people with suspected prostate cancer